Michael A. Metzger
Chief Executive Officer at Syndax Pharmaceuticals Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 2 boards, counting each seat separately. Longest: Syndax Pharmaceuticals Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Pyxis Oncology Inc. June 15, 202690.5%
-
Syndax Pharmaceuticals Inc. June 10, 202698.9%
-
Syndax Pharmaceuticals Inc. May 17, 202397.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 8, 2026 | Syndax Pharmaceuticals Inc. | Option exercise | +32,375 | $6.38 | $206,553 |
| Jul 8, 2026 | Syndax Pharmaceuticals Inc. | Open-market sale | −32,375 | $24.24 | $784,770 |
| Jun 1, 2026 | Syndax Pharmaceuticals Inc. | Open-market sale | −6,847 | $18.99 | $130,025 |
| Feb 9, 2026 | Syndax Pharmaceuticals Inc. | Open-market sale | −17,159 | $21.03 | $360,854 |
| Feb 6, 2026 | Syndax Pharmaceuticals Inc. | Open-market sale | −7,412 | $20.62 | $152,835 |
| Feb 4, 2026 | Syndax Pharmaceuticals Inc. | Grant or award | +73,000 | — | — |
| Feb 4, 2026 | Syndax Pharmaceuticals Inc. | Grant or award | +144,600 | — | — |
| Sep 8, 2025 | Syndax Pharmaceuticals Inc. | Option exercise | +157,307 | $10.90 | $1,714,646 |
| Sep 8, 2025 | Syndax Pharmaceuticals Inc. | Open-market sale | −157,307 | $16.41 | $2,581,408 |
| Jul 16, 2025 | Syndax Pharmaceuticals Inc. | Open-market sale | −7,534 | $9.29 | $69,991 |
| Mar 14, 2025 | Syndax Pharmaceuticals Inc. | Option exercise | +6,074 | $7.20 | $43,733 |
| Mar 4, 2025 | Syndax Pharmaceuticals Inc. | Option exercise | +7,814 | $7.20 | $56,261 |
| Mar 4, 2025 | Syndax Pharmaceuticals Inc. | Open-market sale | −7,814 | $15.05 | $117,601 |
| Feb 10, 2025 | Syndax Pharmaceuticals Inc. | Open-market sale | −13,288 | $15.50 | $205,964 |
| Feb 5, 2025 | Syndax Pharmaceuticals Inc. | Grant or award | +60,500 | — | — |
Questions about Michael A. Metzger
What boards is Michael A. Metzger on?
Michael A. Metzger sits on the boards of Pyxis Oncology Inc. and Syndax Pharmaceuticals Inc.
What company is Michael A. Metzger the CEO of?
Michael A. Metzger is Chief Executive Officer of Syndax Pharmaceuticals Inc.
How long has Michael A. Metzger served on boards?
Our records show at least 6 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.